Cautious Hold Rating for Prime Medicine, Inc. Amid Promising Preclinical Results and Extended Development Timeline

H.C. Wainwright analyst Arthur He CFA has reiterated their neutral stance on PRME stock, giving a Hold rating on November 11.

Arthur He CFA has given his Hold rating due to a combination of factors surrounding Prime Medicine, Inc.’s current position and future prospects. The company has shown promising preclinical results for its PM577 program targeting Wilson’s Disease, particularly in correcting the H1069Q mutation and restoring normal copper levels in a mouse model. However, the timeline for clinical development is extended, with an IND submission planned for the first half of 2026 and initial clinical data expected in 2027, which suggests a long path to potential market entry.
Furthermore, while there is a significant unmet need in the treatment of Wilson’s Disease, current therapies have notable limitations and side effects, highlighting the potential for PM577 to offer a superior alternative. Despite this potential, the current standard of care remains effective for many patients, and the challenges in adherence to treatment regimens persist. These factors, combined with the early stage of PM577’s development, contribute to a cautious outlook, justifying the Hold rating until further advancements are made.

In another report released on November 11, Citi also maintained a Hold rating on the stock with a $4.25 price target.